More Emyria Ltd news
Emyria LtdASX: EMD

Preclinical studies initiated for MDMA-inspired analogues

Aug 4, 2022 at 12:14 AM EDT · Issued by Emyria Ltd

Filed with ASX · Aug 4, 2022 at 12:14 AM EDT

On 6ix: 6ix.com/news/preclinical-studies-initiated-for-mdma-inspired-analogues

Emyria Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Emyria Ltd on 6ix

Earlier from Emyria

  • Appendix 4C - QuarterlyJul 27, 2022
  • Emyria expands drug candidate library inspired by MDMAJul 17, 2022
  • Emyria expands MDMA analogue program with UWAMay 31, 2022
  • EMD-RX5 demonstrates excellent safety and bioavailabilityMay 24, 2022
  • Further positive MDMA analogue screening results receivedMay 9, 2022

Later from Emyria

  • Emyria receives ethics approval for EMD-RX5 Phase 3 trialAug 16, 2022
  • Positive results received for Emyrias MDMA-inspired programAug 17, 2022
  • Appendix 4E and Annual ReportAug 29, 2022
  • Emyria commences US preclinical program for MDMA librarySep 19, 2022
  • Emyria expands clinical sites for EMD-RX5 Phase 3 trialSep 25, 2022
All Emyria news releases↗

Follow Emyria into a list and get an email when it puts out news.

Follow Emyria
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer